Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of a therapeutic agent for the treatment of alcohol use disorder (AUD). Its lead drug product is AD04. AD04 is a selective serotonin-3 antagonist. AD04 can also be used for the treatment of other addictive disorders, such as obesity, smoking, and drug addiction. The Company has completed a Phase-II clinical trials of AD04.